Leen Rigouts

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8761367/publications.pdf

Version: 2024-02-01

85 papers	4,729 citations	136940 32 h-index	106340 65 g-index
94 all docs	94 docs citations	94 times ranked	4011 citing authors

#	Article	IF	Citations
1	Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiology, 2006, 6, 23.	3.3	900
2	A standardised method for interpreting the association between mutations and phenotypic drug resistance inMycobacterium tuberculosis. European Respiratory Journal, 2017, 50, 1701354.	6.7	273
3	Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nature Reviews Microbiology, 2019, 17, 533-545.	28.6	237
4	Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard. Journal of Clinical Microbiology, 2013, 51, 2633-2640.	3.9	216
5	Rifampin Resistance Missed in Automated Liquid Culture System for Mycobacterium tuberculosis Isolates with Specific rpoB Mutations. Journal of Clinical Microbiology, 2013, 51, 2641-2645.	3.9	186
6	Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results. Journal of Clinical Microbiology, 2009, 47, 3501-3506.	3.9	167
7	Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infectious Diseases, The, 2016, 16, 1185-1192.	9.1	151
8	A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes region. Nature Communications, 2020, 11, 2917.	12.8	136
9	Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respiratory Research, 2006, 7, 99.	3.6	135
10	Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 621-630.	5.6	131
11	Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infectious Diseases, The, 2018, 18, 675-683.	9.1	119
12	The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe, The, 2022, 3, e265-e273.	7.3	114
13	GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. Nature Communications, 2019, 10, 2128.	12.8	111
14	Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Medicine, 2016, 14, 31.	5.5	102
15	Disputed <I>rpo</I>B mutations can frequently cause important rifampicin resistance among new tuberculosis patients. International Journal of Tuberculosis and Lung Disease, 2015, 19, 185-190.	1.2	90
16	Community-Based Active Tuberculosis Case Finding in Poor Urban Settlements of Phnom Penh, Cambodia: A Feasible and Effective Strategy. PLoS ONE, 2014, 9, e92754.	2.5	88
17	SpecificgyrAgene mutations predict poor treatment outcome in MDR-TB. Journal of Antimicrobial Chemotherapy, 2016, 71, 314-323.	3.0	86
18	Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Scientific Reports, 2018, 8, 15382.	3.3	75

#	Article	IF	Citations
19	Rifampin Heteroresistance in Mycobacterium tuberculosis Cultures as Detected by Phenotypic and Genotypic Drug Susceptibility Test Methods. Journal of Clinical Microbiology, 2013, 51, 4220-4222.	3.9	70
20	Zoonotic tuberculosis and brucellosis in Africa: neglected zoonoses or minor public-health issues? The outcomes of a multi-disciplinary workshop. Annals of Tropical Medicine and Parasitology, 2009, 103, 401-411.	1.6	69
21	Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. European Respiratory Journal, 2021, 57, 2002338.	6.7	58
22	Reference set of Mycobacterium tuberculosis clinical strains: A tool for research and product development. PLoS ONE, 2019, 14, e0214088.	2.5	56
23	Direct Detection of Mycobacterium tuberculosis Complex DNA and Rifampin Resistance in Clinical Specimens from Tuberculosis Patients by Line Probe Assay. Journal of Clinical Microbiology, 2006, 44, 4384-4388.	3.9	54
24	Can Molecular Methods Detect 1% Isoniazid Resistance in Mycobacterium tuberculosis?. Journal of Clinical Microbiology, 2013, 51, 1596-1599.	3.9	52
25	Clinical practice. European Journal of Pediatrics, 2009, 168, 1285-1290.	2.7	51
26	GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings. PLoS ONE, 2015, 10, e0137471.	2.5	47
27	Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains. Journal of Clinical Microbiology, 2020, 58, .	3.9	46
28	Newly Developed Primers for Comprehensive Amplification of the rpoB Gene and Detection of Rifampin Resistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2007, 45, 252-254.	3.9	41
29	Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. Journal of Antimicrobial Chemotherapy, 2015, 70, 2300-2305.	3.0	41
30	Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations. Scientific Reports, 2019, 9, 11760.	3.3	40
31	Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a diagnostic evaluation study. Clinical Microbiology and Infection, 2019, 25, 1000-1005.	6.0	40
32	Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance. Scientific Reports, 2019, 9, 11826.	3.3	38
33	Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. International Journal of Tuberculosis and Lung Disease, 2007, 11, 189-94.	1.2	38
34	How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?. Journal of Clinical Microbiology, 2019, 57, .	3.9	36
35	Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. Lancet Microbe, The, 2020, 1, e74-e83.	7.3	35
36	Reconstituting the genus Mycobacterium. International Journal of Systematic and Evolutionary Microbiology, 2021, 71, .	1.7	34

#	Article	IF	Citations
37	Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones inMycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2016, 71, 1233-1240.	3.0	32
38	The predominance of Ethiopian specific Mycobacterium tuberculosis families and minimal contribution of Mycobacterium bovis in tuberculous lymphadenitis patients in Southwest Ethiopia. Infection, Genetics and Evolution, 2017, 55, 251-259.	2.3	28
39	How should discordance between molecular and growth-based assays for rifampicin resistance be investigated?. International Journal of Tuberculosis and Lung Disease, 2017, 21, 721-726.	1.2	27
40	Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda. International Journal of Tuberculosis and Lung Disease, 2020, 24, 329-339.	1.2	26
41	Geographic Differences in the Contribution of ubiA Mutations to High-Level Ethambutol Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 4101-4105.	3.2	24
42	Genotypic characterization directly applied to sputum improves the detection of Mycobacterium africanum West African 1, under-represented in positive cultures. PLoS Neglected Tropical Diseases, 2017, 11, e0005900.	3.0	24
43	Implementation Validation Performed in Rwanda To Determine Whether the INNO-LiPA Rif.TB Line Probe Assay Can Be Used for Detection of Multidrug-Resistant Mycobacterium tuberculosis in Low-Resource Countries. Journal of Clinical Microbiology, 2007, 45, 3111-3114.	3.9	22
44	Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment. Clinical Microbiology and Infection, 2018, 24, 60-64.	6.0	21
45	Evaluation of the GenotypeÂ® MTBDR<I>plus</I> assay as a tool for drug resistance surveys. International Journal of Tuberculosis and Lung Disease, 2011, 15, 959-965.	1.2	20
46	Increased detection of smear-negative pulmonary tuberculosis by GeneXpert MTB/RIFÂ® assay after bleach concentration. International Journal of Mycobacteriology, 2016, 5, 211-218.	0.6	20
47	Standardization of a TaqMan-Based Real-Time PCR for the Detection of Mycobacterium tuberculosis-Complex in Human Sputum. American Journal of Tropical Medicine and Hygiene, 2014, 91, 709-714.	1.4	19
48	Low Occurrence of Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a Long-Running DOTS Program in Zambia. Tuberculosis Research and Treatment, 2010, 2010, 1-6.	0.6	18
49	Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations. Journal of Clinical Microbiology, 2018, 56, .	3.9	18
50	Post-mortem examination and laboratory-based analysis for the diagnosis of bovine tuberculosis among dairy cattle in Ecuador. Preventive Veterinary Medicine, 2011, 101, 65-72.	1.9	16
51	Bacteriological methods as add on tests to fine-needle aspiration cytology in diagnosis of tuberculous lymphadenitis: can they reduce the diagnostic dilemma?. BMC Infectious Diseases, 2014, 14, 720.	2.9	15
52	Comparative genomics shows differences in the electron transport and carbon metabolic pathways of Mycobacterium africanum relative to Mycobacterium tuberculosis and suggests an adaptation to low oxygen tension. Tuberculosis, 2020, 120, 101899.	1.9	15
53	Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal, 2022, 59, 2200166.	6.7	15
54	First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea. Infection, Genetics and Evolution, 2015, 33, 314-319.	2.3	14

#	Article	IF	Citations
55	PRELIMINARY OBSERVATIONS ON MYCOBACTERIUM SPP. IN DAIRY CATTLE IN ECUADOR. American Journal of Tropical Medicine and Hygiene, 2006, 75, 318-323.	1.4	14
56	Comparative Intradermal Tuberculin Test in Dairy Cattle in the North of Ecuador and Risk Factors Associated with Bovine Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2009, 81, 1103-1109.	1.4	13
57	Targeted next-generation sequencing of sputum for diagnosis ofÂdrug-resistant TB: results of a national survey in DemocraticÂRepublic of theÂCongo. Scientific Reports, 2020, 10, 10786.	3.3	13
58	Low sensitivity of the MPT64 identification test to detect lineage 5 of the Mycobacterium tuberculosis complex. Journal of Medical Microbiology, 2018, 67, 1718-1727.	1.8	13
59	Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout. International Journal of Tuberculosis and Lung Disease, 2012, 16, 455-461.	1.2	12
60	Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm. Clinical Microbiology and Infection, 2014, 20, 1015-1020.	6.0	12
61	Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen. International Journal of Infectious Diseases, 2020, 100, 357-365.	3.3	12
62	Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results. JMIR Medical Informatics, 2018, 6, e12.	2.6	11
63	Mycobacterium tuberculosis complex lineage 5 exhibits high levels of within-lineage genomic diversity and differing gene content compared to the type strain H37Rv. Microbial Genomics, 2021, 7, .	2.0	9
64	Systematic screening for drug-resistant tuberculosis with Xpert^{Â®} MTB/RIF in a referral hospital in Cambodia. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1528-1535.	1.2	8
65	Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic Tests. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	8
66	Broad diversity of Mycobacterium tuberculosis complex strains isolated from humans and cattle in Northern Algeria suggests a zoonotic transmission cycle. PLoS Neglected Tropical Diseases, 2020, 14, e0008894.	3.0	8
67	The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide. International Journal of Mycobacteriology, 2016, 5, S46-S47.	0.6	7
68	Genetic diversity of the Mycobacterium tuberculosis complex strains from newly diagnosed tuberculosis patients in Northwest Ethiopia reveals a predominance of East-African-Indian and Euro-American lineages. International Journal of Infectious Diseases, 2021, 103, 72-80.	3.3	7
69	Multidrug-resistant patients receiving treatment in Niger who are infected with M. tuberculosis Cameroon family convert faster in smear and culture than those with M. tuberculosis Ghana family. Tuberculosis, 2020, 122, 101922.	1.9	6
70	Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1443-1446.	1.4	6
71	Diverse Molecular Genotypes ofMycobacterium tuberculosisComplex Isolates Circulating in the Free State, South Africa. International Journal of Microbiology, 2016, 2016, 1-7.	2.3	5
72	Is frontloaded sputum microscopy an option in active tuberculosis case finding?. International Journal of Tuberculosis and Lung Disease, 2015, 19, 91-96.	1.2	4

#	Article	IF	Citations
73	Storage of Sputum in Cetylpyridinium Chloride, OMNIgene.SPUTUM, and Ethanol Is Compatible with Molecular Tuberculosis Diagnostic Testing. Journal of Clinical Microbiology, 2019, 57, .	3.9	3
74	Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali. International Journal of Tuberculosis and Lung Disease, 2020, 24, 763-769.	1.2	3
75	Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in rural Bangladesh: lessons learnt. Public Health Action, 2012, 2, 76-78.	1.2	2
76	Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022, 27, 100299.	1.3	2
77	Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study. Antimicrobial Agents and Chemotherapy, 2022, 66, e0207521.	3.2	2
78	Use of RODAC plates to measure containment of Mycobacterium tuberculosis in a Class IIB biosafety cabinet during routine operations. International Journal of Mycobacteriology, 2016, 5, 148-154.	0.6	1
79	Multicentre study to establish interpretive criteria for clofazimine drug susceptibility testing. International Journal of Tuberculosis and Lung Disease, 2019, 23, 594-599.	1.2	1
80	False Rifampicin Resistance in Xpert Ultra Applied to Lymph Node Aspirate: A Case Report. Open Forum Infectious Diseases, 2020, 7, ofaa204.	0.9	1
81	Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial. International Journal of Tuberculosis and Lung Disease, 2021, 25, 839-845.	1.2	1
82	Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1257-1264.	1.4	0
83	Management of falsepositive rifampicin resistant Xpert MTB/RIF â€“ Authors' reply. Lancet Microbe, The, 2020, 1, e239.	7.3	0
84	Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin. BMC Infectious Diseases, 2021, 21, 979.	2.9	0
85	Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings. JAC-Antimicrobial Resistance, 2022, 4, dlac037.	2.1	0